Member Info for Laura2022

Sareum board

https://www.bbc.co.uk/news/articles/ck77k80nlwro

Thankyou

I hope you don't mind me using this for PYC bulletin board due to their A.I work with various clients...such as Sareum

Thankyou Freddie

Company is in the final stages of negotiation for two projects (one with an existing client and one with a potential new client), the total value of which is expected to be, in aggregate, approximately £350k

From a poster who

1 says they know about former directors family

2 been invested for 20yrs (not sure if PYC or stocks generally) but has averaged of 1.38p ??

3 knows about past and current PYC technology

4 accuses others of working for the company just hours before an RNS having complained about lack of newsflow but adds no comment

Very strange

Wow

17 on the list and PYC already work with 5th and 7th (Bicycle and Cellcentric)

Excentia would be amazing Debull

Amazing links Debull thankyou

You are correct, I should have directly given you the credit for the A.i link yesterday

Please accept my short conings

Usually alot to say but now nothing

I'm sure sentiment will improve, there has been some strange comments on here from others and would be nice to get back to the harmony we enjoyed previously

Have a great weekend everyone

Clearly more and more companies are seeing the value of PYC technologies

AI-discovered drugs in Phase I clinical trials have an 80-90 per cent success rate, far outpacing drugs discovered by humans, new research has found.

Human-discovered drugs have an average success rate of 40-65 per cent in Phase I.

The new BCG research is published in the journal Drug Discovery Today.

The study is the first analysis of the industry-wide pipeline of AI-discovered drugs and vaccines, focusing on clinical success rates.

EDINBURGH, Scotland, Nov. 27, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the FDA  provides clearance on the Company's investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML).

Bicycle

AstraZeneca

Glaxo ??

Any ideas ?

Ilovesushi pops up every 3mths

Yet was promoting CPX at 2p pre Christmas that now lost 99% of value and is also in a company where BOD have been accused of corruption

He's an irritant

Skier and kingh

£1.7mln market value is ridiculous

be, in aggregate, approximately £350k. Whilst the Board anticipates that the contracts for these two projects will be signed in FY24, the majority of the revenue is now expected be recognised in the Company's next financial year ending 30 June 2025 ("FY25"), and accordingly the Board's expectations for FY25 revenues have been correspondingly increased. 

The Board notes that the Company has, to date, secured £225k of revenue in respect of FY25 which is expected to increase to over £0.5 million on the signing of the two aforementioned contracts.

 

Dr Pete Sargent, CEO, commented:

"Whilst we are clearly disappointed that the execution of these two large contracts has been delayed, we have a high level of confidence that they will be signed before the end of this financial year. Assuming that is achieved, and taking account of the anticipated value of these two contracts, the Company would then be going into its next financial year with one of its highest ever levels of signed projects."

 

£160k is largest single contract (£125k previously) and suggests the 2nd one due is £180k+ (see may update)

Personalised medicine solutions, is pleased to announce that it has been awarded a significant contract by a new UK-based biotech client. This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas. The project involves the use of our proprietary Virtual Tumour technology to help guide the Phase 1b/2 dosing regimens for one of their oncology assets and benchmark it against the competition. The project is valued at £161,580 and is anticipated to be completed over the next five months. The project, and associated contract award, is one of the two referred to in the Company's trading update on 3 May 2024.

What a ridiculous claim to make

Particularly when I post on over 20 stocks while several on here only post on PYC some of whom claims to have spoken to the company/ and or known for example that the director who left wanted to spend me time with his family whichis either

1 a lie

2 a guess

3 a fact only known if one knows the company

I see the selective ignoring continues, pretty poor tbh

I'll keep my detailed company reply to myself as clearly its a boys club now

Thankyou Hard up

LLOYD and BARC virtually at 12mth and 5yr highs respectively